A helminth-derived chitinase structurally similar to mammalian chitinase displays immunomodulatory properties in inflammatory lung disease by Ebner, F. et al.
Research Article
A Helminth-Derived Chitinase Structurally Similar to
Mammalian Chitinase Displays Immunomodulatory Properties in
Inflammatory Lung Disease
Friederike Ebner ,1 Katja Lindner,1 Katharina Janek,2 Agathe Niewienda,2
Piotr H. Malecki,3,4 Manfred S. Weiss ,3 Tara E. Sutherland,5 Arnd Heuser,6 Anja A. Kühl,7
Jürgen Zentek,8 Andreas Hofmann,9 and Susanne Hartmann 1
1Institute of Immunology, Department of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany
2Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health,
Institute of Biochemistry, Shared Facility for Mass Spectrometry, Berlin, Germany
3Macromolecular Crystallography (HZB-MX), Helmholtz-Zentrum Berlin, Berlin, Germany
4Department of Structural Biology of Prokaryotic Organisms, Institute of Bioorganic Chemistry, Polish Academy of Science, Poland
5Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health
Science Centre, University of Manchester, Manchester, UK
6Max Delbrück Center for Molecular Medicine (MDC), Pathophysiology Platform, Berlin, Germany
7Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, iPATH.Berlin, Berlin, Germany
8Institute of Animal Nutrition, Department of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany
9Department of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville,
Victoria 3010, Australia
Correspondence should be addressed to Susanne Hartmann; susanne.hartmann@fu-berlin.de
Friederike Ebner and Katja Lindner contributed equally to this work.
Received 2 September 2021; Accepted 25 October 2021; Published 25 November 2021
Academic Editor: Yolanda González
Copyright © 2021 Friederike Ebner et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Immunomodulation of airway hyperreactivity by excretory-secretory (ES) products of the first larval stage (L1) of the
gastrointestinal nematode Trichuris suis is reported by us and others. Here, we aimed to identify the proteins accounting for
the modulatory effects of the T. suis L1 ES proteins and studied six selected T. suis L1 proteins for their immunomodulatory
efficacy in a murine OVA-induced allergic airway disease model. In particular, an enzymatically active T. suis chitinase
mediated amelioration of clinical signs of airway hyperreactivity, primarily associated with suppression of eosinophil
recruitment into the lung, the associated chemokines, and increased numbers of RELMα+ interstitial lung macrophages.
While there is no indication of T. suis chitinase directly interfering with dendritic cell activation or antigen presentation to
CD4 T cells, treatment of allergic mice with the worm chitinase influenced the hosts’ own chitinase activity in the
inflamed lung. The three-dimensional structure of the T. suis chitinase as determined by high-resolution X-ray
crystallography revealed high similarities to mouse acidic mammalian chitinase (AMCase) but a unique ability of T. suis
chitinase to form dimers. Our data indicate that the structural similarities between the parasite and host chitinase
contribute to the disease-ameliorating effect of the helminth-derived chitinase on allergic lung inflammation.
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1. Introduction
Chronic helminth infections are known to be accompanied
by various immunomodulatory processes. The active modu-
lation of host immune responses is believed to ensure long-
term persistence of the parasites and most likely involves
proteins released by the worms (reviewed in [1–3]). Over
the last decade, research has focused on identifying secreted
helminth immunomodulators and mechanisms of suppres-
sion in order to understand natural infection and in parallel
with the aim to exploit this knowledge for the benefit of
unwanted human inflammatory diseases.
We and others have identified secreted products with
immunosuppressive effects in autoimmune and inflamma-
tory diseases from diverse parasitic helminths such as
Acanthocheilonema viteae [4–11], Schistosoma [12–15], Fas-
ciola hepatica [16, 17], Heligmosomoides polygyrus [18, 19],
and Wuchereria bancrofti [20, 21]. Among the organisms
currently explored for helminth-induced therapy of humans
are the pig whipworm (Trichuris suis, TSO), the human
hookworm (Necator americanus, NC), and also the human
whipworm (T. trichiura, TTO). As T. suis can be easily
maintained in pigs but cannot multiply in humans, its
administration as live parasite (TSO therapy) has been tested
in a variety of clinical studies to improve human immune
disorders (reviewed in [22]). Early success stories of treat-
ments of ulcerative colitis (UC) and Crohn’s disease (CD)
with TSO [23–25] were followed by larger trials with only
modest results for various autoimmune diseases [22,
26–28] and implicated the need for a greater understanding
for the immunomodulatory mechanisms. In a rather small
cohort of MS patients receiving controlled TSO treatment,
we demonstrated varying degrees of parasite-specific T cell
responses and cellular functionality across individuals
receiving treatment, indicating the need to understand
responders and nonresponders in order to develop more tai-
lored treatment regimens [29].
T. suis has a direct life cycle. Upon ingestion of larval
stage 1 (L1) containing infective eggs, the larvae hatch and
invade the mucosa of the large intestine and develop into
adults by molting several times [30]. When administered
therapeutically to humans, there is evidence for a self-limit-
ing, sterile colonization of T. suis [23]; thus, repeated TSO
treatments are required. However, this transient exposure
highlights the role of early larval stages to possess immuno-
modulatory properties. Using soluble products (Ts-SPs) or
excretory-secretory proteins (Ts-ES) or isolated fractions
from both adult worms and larval stages, several immuno-
modulatory mechanisms have been investigated [31–34].
Ts-SPs from adult worms have been shown to interfere with
activation of human dendritic cells and macrophages [32,
35–38]. We have previously reported on the immunomodu-
latory activity of proteins collected from Ts L1 which inter-
fere with CD4+ T cell priming and clinical parameters of
experimental airway hyperreactivity [34]. Similarly, a recent
study shows that Ts-ES proteins released by adult and larval
stages of T. suis possess anti-inflammatory properties.
Indeed, the authors identified a subset of proteins with
anti-inflammatory properties within adult Ts-ES [31]. How-
ever, immunoregulators of the very early larval stages of T.
suis remain elusive.
Here, we focus on the identification and characterization
of proteins selectively secreted by the first larval stages of T.
suis. We screened a set of n = 6 recombinant larval proteins
for immunomodulatory properties and identified an enzy-
matically active T. suis chitinase that interfered with recruit-
ment of immune cells and inflammatory reactions in a
murine model of allergic airway disease. While our in vitro
data suggest no direct immunomodulatory effects on, e.g.,
DC function or T cell activation, we observed disease ame-
lioration to be associated with suppression of eosinophil
recruitment into the lung and increased numbers of alterna-
tively activated RELMα+ lung macrophages. X-ray crystal-
lography revealed the structure of the nematode enzyme to
be highly similar to the host’s own chitinases. Since mamma-
lian host chitinases, both true chitinases with enzymatic
activity (AMCase and chitotriosidase) and chitinase-like
protein (CLP) molecules which can bind to chitin but lack
enzymatic activity, are implicated as either mediators or
biomarkers involved in airway inflammation and fibrosis,
disease amelioration by treating with a worm chitinase was
rather surprising. Our findings further reveal that T. suis
chitinase treatment of allergic mice not only inhibited host
AMCase expression on mRNA level but also interfered with
host chitinase activity in the BAL fluid, suggesting an alter-
native mechanism that might involve the high degree of
structural similarity between host and nematode chitinases.
2. Materials and Methods
2.1. Ethics Statement. Mice were cared for in accordance
with the principles outlined in the European Convention
for the Protection of Vertebrate Animals used for Experi-
mental and other Scientific Purposes and the German Ani-
mal Welfare Law. The mouse study was approved by the
State Office of Health and Social Affairs Berlin, Germany
(Landesamt für Gesundheit und Soziales; approval numbers
G0144/10, T0407/17, and G0068/16).
The T. suis life cycle was maintained in pigs (Sus scrofa)
in accordance with the principles outlined in the European
Convention for the Protection of Vertebrate Animals used
for Experimental and other Scientific Purposes and the Ger-
man Animal Welfare Law. The generation of larval material
was approved by the State Office of Health and Social Affairs
Berlin, Germany (Landesamt für Gesundheit und Soziales;
approval number H0296/12).
2.2. Animals. Female BALB/c mice were purchased from
Janvier Labs (Le Genest-Saint-Isle, France) and maintained
together with DO11.10 (OVA-TCR tg) mice at the Institute
of Immunology, Department of Veterinary Medicine in Ber-
lin. DO11.10 were typed for expression of the transgenic (tg)
T cell receptor (TCR) using flow cytometry, and only mice
with more than 90% of the CD4+ T cells expressing the
OVA-tg TCR were used in the study. The T. suis life cycle
was maintained in pigs (Sus scrofa) bred and cared for at
the Institute of Animal Nutrition, Department of Veterinary
Medicine in Berlin.
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2.3. Murine OVA-Induced Allergic Airway Disease. Allergic
airway inflammation was induced as previously described
[4]. Briefly, female BALB/c mice (8 weeks old) were sensi-
tized on days 0 and 14 with 20μg ovalbumin protein
(OVA, grade VI, Sigma-Aldrich Chemie GmbH, Munich,
Germany) emulsified in 2mg alum (Imject™ Alum, Ther-
moFisher Scientific, IL, USA). Nonallergic control animals
(PBS) received equal volumes of PBS on days 0 and 14
instead of OVA. Mice were treated with 20μg recombinant,
intact T. suis proteins or heat-inactivated proteins on days 0,
7, and 14 i.p. or left untreated. Intranasal OVA challenge
(50μg OVA/25μl PBS) was performed on all groups of mice
on days 28 and 29. Where indicated, lung function was
assessed on day 30 at the Max Delbrück Center for Molecu-
lar Medicine (MDC) in Berlin. On day 31, mice were sacri-
ficed, bronchoalveolar lavage (BAL) was performed, and
samples were taken for analysis.
2.4. Airway Hyperreactivity. Airway resistance and lung
function were assessed via double-chamber plethysmogra-
phy (emka Technologies, Paris, France) in response to
increasing doses of acetyl-ß-methylcholine (Methacholine,
Sigma-Aldrich Chemie GmbH, Munich, Germany).
Mice were placed into a restrainer without anesthesia
and adjusted (5min), and the following protocol was
applied: baseline measurement (4min), PBS (1min), mea-
surement (4min), 6.25mg/ml methacholine (1min), mea-
surement (4min), 12.5mg/ml methacholine (1min),
measurement (4min), 25mg/ml (1min) methacholine, mea-
surement (4min), 50mg/ml methacholine (1min), and mea-
surement (4min).
Data were sampled once per second. For data analysis,
averages of 5 sec intervals were used. Airway resistance
(Sraw) and expiratory time values were generated and ana-
lyzed using iox2 software (iox v2.8.0.13, emka Technologies).
Resulting data points were averaged again per mouse and
methacholine dose. Data points with success rate < 50% and
beat number < 10 were excluded from the analysis.
2.5. Bronchoalveolar Lavage. Intratracheal bronchoalveolar
lavage (BAL) was performed on i.p. anaesthetized mice by
inflating the lungs with 800μl PBS containing protease
inhibitor cocktail (cOmplete™, Mini, EDTA-free Protease
Inhibitor, Roche Diagnostics GmbH, Mannheim, Germany).
The 1st BAL was pelleted, and the supernatant was stored at
-20°C for cytokine/chemokine detection. Four additional
lavages (4 × 800μl PBS) were performed for cell isolation
and pelleted by centrifugation. All cells were pooled in
500μl PBS and counted using a Neubauer cell chamber. 2
× 100μl cell suspension per sample was used for cytospin
preparation. Object slides were dried and stained with Diff-
Quick solutions (Labor und Technik Eberhard Lehmann
GmbH, Berlin, Germany) for differential cell counts. Resid-
ual cells were used for flow cytometry.
2.6. Histology and Immunohistochemistry. Following lung
lavage, the left lobe was split into two pieces. The lower tis-
sue was degassed and fixed in a formalin solution (Roti-His-
tofix 10%, Carl Roth GmbH + Co. KG, Karlsruhe, Germany)
for 6 h at room temperature and then stored at 4°C. The tis-
sue was embedded in paraffin, and sections were stained
with an antibody against RELM-α (polyclonal rabbit anti-
mouse, Abcam, Cambridge, UK). Nuclei were stained with
hematoxylin (Merck). Interstitial RELM-α+ cells were quan-
tified in 5HPF (high-power fields, 400x magnification). Pic-
tures are presented at 400x magnification. For evaluation of
histomorphological changes, paraffin sections were stained
with hematoxylin and eosin (H&E) and scored for inflam-
mation and goblet cell hyperplasia. Briefly, score 1 is for
minor perivascular inflammation, score 2 for moderate peri-
vascular and peribronchial inflammation and minimal gob-
let cell hyperplasia, score 3 for increased perivascular and
peribronchial inflammation and increased goblet cell hyper-
plasia (beginning in smaller airways), and score 4 for severe
perivascular, peribronchial, and interstitial inflammation
with goblet cell hyperplasia in smaller and larger airways.
2.7. Generation of Bone Marrow-Derived Dendritic Cell (DC)
and Activation Assay. Isolated bone marrow cells from the
tibia and femur of female BALB/c mice were seeded at 5 ×
105 cells/ml in 10ml RPMI-1640 media (PAN-Biotech) con-
taining 10% fetal calf serum (FCS), 20mM L-glutamine,
100U/ml penicillin, and 100μg/ml streptomycin (PAN-Bio-
tech) and differentiated in the presence of recombinant GM-
CSF (20 ng/μl) (PeproTech). At days 6–8, nonadherent cells
were collected. For studying effects of Ts-Chit on DC activa-
tion, BM-DCs were preincubated with 10μg/ml recombi-
nant Ts-Chit protein for 2.5 h and stimulated with 100 ng/
ml LPS-B5 (Sigma-Aldrich Chemie GmbH, Munich, Ger-
many) or 1μM CpG (ODN 1668, InvivoGen, CA, USA)
for additional 20 h. Cell culture supernatants were collected
and stored at -20°C for cytokine ELISA, and DCs were ana-
lyzed for activation markers CD86, MHCII, and Ox40-L by
flow cytometry.
2.8. T Cell Proliferation Assays In Vitro. For studying effects
of Ts-Chit on antigen-independent T cell proliferation, sple-
nocytes were isolated from female BALB/c mice, labeled
with CFSE in PBS (8min, RT, 5μM), and seeded at a density
of 4 × 106 cells/ml in round-bottom 96-well plates. After 4
days of incubation (37°C, 5% CO2) in the presence of
plate-bound mouse αCD3/αCD28 (1μg/ml) and recombi-
nant Ts-Chit (10μg/ml), DCs were harvested and analyzed
for CFSE dilution in CD4+ and CD8+ T cells.
For studying effects of Ts-Chit on antigen-dependent T
cell proliferation and differentiation, MACS-purified OVA-
TCR tg CD4+ T cells isolated from DO11.10 mice were
labeled with CFSE (5μM, eBioscience) in PBS for 8min at
room temperature. CFSE-labeled CD4+ T cells (4 × 105)
were cocultured with OVA-loaded and Ts-Chit pretreated
BM-DC (1 × 105) for 4 days and analyzed by flow cytometry
for CFSE dilution and Treg/Th transcription factors.
2.9. Multiplex Assay. Bronchoalveolar lavage supernatants
were analyzed for cytokine and chemokine levels using the
Mouse Cytokine & Chemokine 26-Plex ProcartaPlex™ Panel
(ThermoFisher, MA, USA) according to the manufacturer’s
instructions. The MAGPIX™ instrument (Luminex) was
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used, and data were analyzed with ProcartaPlex™ Analyst
1.0.
2.10. Flow Cytometry. The following monoclonal fluoro-
chrome conjugated anti-mouse antibodies were used:
CD11b (clone M1/70, APC-Cy7), CD64 (clone X54-5/7.1,
PE-Cy7), IgG1 (clone RMG1-1, APC), and IgG2a (clone
RMG2a-62, PerCP-Cy5.5) were purchased from BioLegend,
CA, USA. CD45 (clone 30-F11, eF450), MHC-II (clone M5/
114.15.2, PE-Cy5), Gr1 (clone RB6-8C5, PE-Cy7), and
EpCAM (clone G8.8, APC) were purchased from
eBioscience, CA, USA. CD11c (clone HL3, FITC), MHC-II
(clone M5/114.15.2, PE), CD86 (clone GL1, Pe-Cy7), IL-13
(clone eBio13A, A488), CD4 (clone RM4-5, Horizon
V500), GATA3 (clone TWAJ, A660), Foxp3 (clone FJK-
16s, PE), Tbet (4B10, BV 421), and SiglecF (clone E50-
2440, PE) were purchased from BD Biosciences, CA, USA.
Viability dye in eFluor 506, eF660, and eF780 and streptavi-
din (FITC) were purchased from eBioscience, CA, USA.
Polyclonal biotinylated anti-mouse RELM-α was purchased
from PeproTech, NJ, USA. Samples were acquired using
Canto II (BD Biosciences, CA, USA) and analyzed using
FlowJo software v9, Tristar.
2.11. Quantitative RT-PCR. Following lung lavage, the upper
right lobe was snap-frozen in liquid nitrogen and stored at
-80°C. RNA isolation from lung tissues was performed using
the innuPREP RNA Mini Kit (Analytic Jena AG, Jena, Ger-
many) according to the manufacturer’s instructions. Reverse
transcription of 1μg RNA into cDNA was done using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, CA, USA). RT-PCR was performed on the
LightCycler® 480 instrument using the LightCycler® 480
SYBR Green I Master Mix (Roche Diagnostics, Mannheim,
Germany) and oligonucleotides listed in Table 1. Gene
expression is described relative to the housekeeping gene
peptidylprolyl isomerase A (PPIA) and normalized to
mRNA levels of the PBS group if not indicated differently.
2.12. Isolation of T. suis Larvae and Production of Excretory-
Secretory (ES) Proteins. Pigs were orally infected with 8000
embryonated T. suis eggs in 2ml NaCl (0.9%). Following
euthanasia on days 10, 18, and 28dpi, T. suis larvae were
manually collected from the caecum and colon. Larvae were
washed 4 times for 15min each in RPMI-1640 (PAN-Bio-
tech, Aidenbach, Germany) supplemented with 200U/ml
penicillin, 200μg/ml streptomycin, and 1.35μg/ml ampho-
tericin B (all purchased from PAN-Biotech) by sedimenta-
tion and incubated overnight in RPMI-1640 supplemented
with 1% glucose (Sigma-Aldrich, St. Louis, US), 100U/ml
penicillin, 100μg/ml streptomycin, and 0.625μg/ml ampho-
tericin B. Culture medium was replaced, and larvae were
incubated for another 5 days while conditioned media were
collected every 2nd day, sterilized by filtration (0.45μmMin-
isart Syringe Filter, Sartorius AG, Göttingen, Germany), and
stored at -20°C.
T. suis L1 ES proteins were isolated from freshly hatched
larvae as previously described [34]. Identification of T. suis
larva ES proteins (in vitro-hatched L1, 10 dpi, 18 dpi, and
28 dpi) was done by mass spectrometry as previously
described [34]. In brief, TCA-precipitated dried protein pel-
lets of T. suis were suspended, reduced, alkylated, and tryptic
digested. The resulting peptides were analyzed by LC-MSMS
on a 4700 Proteomics Analyzer (ABSCIEX, Framingham,
MS). Database searches were performed with Mascot software
against NCBI database 20150331 (64057457 sequences). Pro-
teins were accepted as identified if at least two MS/MS spectra
provided a MASCOT score for identity (p < 0:01Þ.
2.13. Recombinant Protein Expression. T. suis mRNA was
isolated out of 10-20mg worms by using the innuPREP
RNA Mini Kit (Analytic Jena AG, Jena, Germany) according
to manufacturer’s instructions. Reverse transcription of 1μg
RNA into cDNA was done using the Transcriptor First
Strand cDNA Synthesis Kit (Roche Diagnostics GmbH,
Mannheim, Germany).
The genes corresponding to selected T. suis proteins
were amplified and cloned into the vector pLEXSYsat2 of
the Leishmania expression system (LEXSYcon2 Expression
Kit, Jena Bioscience GmbH, Jena, Germany). The cloning
vector was sequenced for verification. Leishmania tarentolae
cells were transfected via electroporation (Nucleofector™ 2b
Device, Amaxa™ Human T Cell Nucleofector™ Kit, Lonza,
Basel, Switzerland) with the respective expression cassette
containing the selective antibiotic marker nourseothricin
(NTC) and the T. suis protein-coding gene. Transfected L.
tarentolae cells were polyclonally selected and maintained
as described in the manual.
2.14. Protein Purification. His6-tag fused, recombinant pro-
teins secreted by transfected Leishmania cells were purified
by liquid chromatography over His-Trap™ excel columns
(GE Healthcare, Buckinghamshire, United Kingdom).
Protein-containing fractions were pooled and dialyzed two
times against PBS (4 h and overnight). Finally, protein con-
centrations were assessed using Pierce™ BCA Protein Assay
Kit (ThermoFisher Scientific, Rockford, USA). Identity of
Table 1: Sequences of oligonucleotides.
Gene Fwd primer (5′-3′) Rev primer (5′-3′)
Chia1 (AMCase) CCCTTGGCATATCCACTGA ACAGAATCCACTGCCTCCAG
Ccl11 (eotaxin1) CTGCTTGATTCCTTCTCTTTCCTAA GGAACTACATGAAGCCAAGTCCTT
Ccl2 (MCP-1) TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT
Arg1 (arginase) CAGAAGAATGGAAGAGTCAG CAGATATGCAGGGAGTCACC
Housekeeping gene PPIA GAGCTGTTTGCAGACAAAGTTC CCCTGGCACATGAATCCTGG
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purified, recombinant proteins was verified by LC-MSMS
analysis after tryptic digestion.
2.15. SDS-PAGE. To validate recombinant expression of T.
suis proteins, a 12% SDS gel was loaded with 1-2μg purified,
recombinant T. suis proteins and developed using silver
staining (Pierce Silver Stain Kit, ThermoFisher Scientific,
Rockford, US).
2.16. Chitinase Assay. Chitinase activity was analyzed by
using the substrate and standard solutions of the fluorimet-
ric chitinase assay kit (Sigma-Aldrich Chemie GmbH,
Munich, Germany). Substrates 4-MU-(GlcNAc)2 (exochiti-
nase activity) and 4-MU-(GlcNAc)3 (endochitinase activity)
were adjusted to 1.1mM in DMSO and diluted 1 : 20 in assay
buffer (100mM citric acid, 200mM sodium phosphate,
pH5.6) immediately prior to starting the assay by adding
50μl of diluted substrate solution to 10μl of protein
KFD48490.1 (Ts-Chit) (5μg/ml). The reaction mix was
incubated for 30min at 37°C and then quenched by adding
500μl stop solution (500mM sodium carbonate, 500mM
sodium bicarbonate, pH10.7). 250μl of the reaction solution
was transferred in duplicate into a black 96-well plate, and
fluorescence of liberated 4-MU was measured using an exci-
tation wavelength of 360nm and recording emission at
450nm. The effect of pH on KFD48490.1/Ts-Chit chitinase
activity was determined by using assay buffers adjusted to
pH = 2, 3, 4, 5, 6, 7, 8, 9, and 10. Heat stability of Ts-Chit
chitinase was assessed by preincubation of the protein for
60min at different temperatures (4°C–90°C) followed by
the chitinase assay.
2.17. Crystallization and X-Ray Data Collection. The recom-
binant protein solution was dialyzed after initial purification
in 20mM HEPES buffer (pH7.5) and purified over a HiLoad
16/600 Superdex 200 pg column with a HEPES running
buffer (20mM HEPES pH7.7, 200mM NaCl, and 1mM
TCEP). Elution fractions were concentrated using Amicon
Ultra-4 concentrator tubes (30,000 MWKO) to a final con-
centration of 33mg/ml. A Gryphon pipetting robot was used
to set up crystallization plates using the JSCG-plus Screen by
mixing 0.25μl protein solution with 0.25μl crystallization
cocktail solution. Plates were sealed and incubated at 20°C.
Crystal growth was monitored regularly under an optical
microscope. The crystals appeared in condition H7 (0.8M
ammonium sulfate, 0.1M BIS-Tris pH5.5, and 25% (w/v)
PEG 3350). Protein crystals were harvested, cryoprotected
using reservoir solution supplemented with 25% (v/v) eth-
ylene glycol, and stored in liquid nitrogen. Diffraction data
were collected on BL14.1 at the BESSY II synchrotron of
the Helmholtz-Zentrum Berlin [39] and processed using
XDSAPP [40]. Relevant processing statistics are shown in
Table 2. The structure was solved by molecular replace-
ment using the structure of human chitotriosidase (CHIT1)
as a search model (PDB-Id 5HBF, [41]). After several
cycles of manual rebuilding using COOT [42] and refine-
ment using REFMAC5 [43], refinement converged at R fac-
tors of 19 and 23% for the working R and the free R,
respectively (Table 3). The refined structure features good
refinement statistics and excellent geometric parameters.
The refined coordinates and the associated structure factor
amplitudes were deposited in the PDB using the accession
code 6G9C.
2.18. Structure-Based Sequence Alignment and Surface
Electrostatics. To obtain an overview of structural similarities
and differences between Ts-Chit and host chitinases, the
topology and secondary structure elements of Ts-Chit were
compared to six mouse chitinases and chitinase-like pro-
teins by means of a structure-based amino acid sequence
alignment (see Supplementary Information S2). Secondary
structure elements were predicted with PSIPRED [44], and
a structure-based amino acid sequence alignment was con-
structed using SBAL [45].
In order to assess whether Ts-Chit possesses any features
that might serve as a potential molecular mimicry of host
chitinases when acting as an antigen, we undertook a com-
parison of surface features of Ts-Chit with mouse chitinases.
In general, this approach is limited by the availability of only
one experimental 3D structure of mouse chitinases. Using
the amino acid sequences of three mouse chitinases (M.
musculus AMCase, Chit1 isoform 1, and Ym1), known 3D
structures or close structural homologues of these proteins
were identified in the PDB using pGenThreader [46], reveal-
ing mouse AMCase as the only mouse protein suitable for
comparison in this context.
Using the monomer and dimer structures of Ts-Chit as
well as the structure of mammalian AMCase (PDB 3FY1),
surface electrostatics for these three proteins were calculated
with APBS [47] and visualized with UCSF Chimera [48].
Table 2: MALDI-TOF MS verified T. suis L1 ES proteins that were selected and recombinantly expressed using LEXSY.
NCBI-ID MW (kDa) Known homology N-Glycosylation O-Glycosylation
KFD48490.1 55.45 Acidic mammalian chitinase (T. trichiura) — 28
KFD55729.1 13.89 — — 1
KFD54802.1 31.06 CAP domain-containing protein (T. trichiura) 3 10
KFD45500.1 37.04 Venom allergen 5 (T. trichiura) 1 24
KFD47618.1 14.18 Hypothetical protein (T. trichiura) — —
KFD53667.1∗ 31.06 Hypothetical protein (T. trichiura) 5 —
Sequence similarity search for protein homology was performed using BLAST/NCBI. Glycosylation prediction was performed using NetOGlyc 4.0.0.13 for O-
glycosylation and NetNGlyc 1.0 Server for N-glycosylation. ∗Formerly identified using HelmDB database and recombinantly expressed based on this
sequence.
5Journal of Immunology Research
2.19. Statistical Analysis. Statistical analysis was done using
GraphPad Prism software v7 (GraphPad Software, Ca, USA)
using the Kruskal-Wallis test (Dunn’s multiple comparisons
test), Mann-Whitney test, or unpaired Student t-test as indi-
cated. Values with p < 0:05 (∗), p<0.005 (∗∗), and p<0.001
(∗∗∗) were considered to be significant.
3. Results
3.1. T. suis L1 Stage-Specific Excretory-Secretory Protein
KFD48490.1 Affects Allergic Airway Inflammation. We pre-
viously showed that T. suis excretory/secretory proteins (ES
proteins) collected from L1 hatched in vitro reduced clinical
signs of murine allergic airway disease [34]. To identify pro-
teins responsible for this effect, we now investigated the pro-
tein composition of L1 ES proteins and compared it to L2,
L3, and L4 larval stages of T. suis-released products. For
stage-specific expression patterns, parasites were isolated
from pigs infected with 8000 TSO at 10, 18, and 28 days
postinfection (resulting in L2, L3, and L4 larvae, respec-
tively) and cultivated to collect conditioned media for mass
spectrometry. Alternatively, eggs were hatched in vitro to
generate L1 larvae and conditioned media, as previously
described [34]. Comparative proteomic analysis of T. suis
ES proteins (Figure 1(a) and Supplementary Table S1)
revealed some overlap between first stage (in vitro hatched)
L1 larvae and L2 larvae (10 day larvae), but no overlap of
L1 ES proteins with later stages of larval development (L3
ES from 18 day larvae and L4 ES from 28 day larvae). Four
L1-specific proteins and two L1/L2-specific proteins with
predicted signal sequences and a lack of transmembrane
domains (Table 2) were recombinantly expressed. Since
glycosylation can be crucial for the immunomodulatory
effects of secreted helminth proteins, we used the
eukaryotic expression system LEXSY, based on the
protozoan L. tarentolae (Figure 1(b)). Notably, selected T.
suis L1 proteins were distinct in size (ranging from 13 to
56 kDa, Figure 1(c)), predicted glycosylation sites and
homology-based annotation (Table 2).
We initially screened for immunomodulatory effects of
the six recombinant T. suis L1 proteins using the OVA-
(ovalbumin-) induced allergic airway hyperreactivity model
in female BALB/c mice. Mice were treated with recombi-
nant T. suis proteins during sensitization with the allergen
OVA on days 0, 7, and 14 (Figure 1(d)). The numbers of
total BAL infiltrates and BAL eosinophils were detected 2
days after the 2nd intranasal OVA challenge at day 31
(Figure 1(d)) and analyzed in parallel to control mice lack-
ing OVA sensitization, but receiving OVA-challenged mice
(PBS) and untreated allergic mice (OVA). Analysis of total
cell numbers and cellular composition of the BAL fluid
found that KFD48490.1 (homologous to T. trichiura acidic
mammalian chitinase) and KFD45500.1 (homologous to T.
trichiura venom allergen 5) reduced the total numbers of
cellular BAL fluid infiltrates, but only KFD48490.1-treated
mice showed a significant reduction of eosinophils infiltrat-
ing the lungs in comparison to untreated allergic (OVA)
mice (Figures 1(e) and 1(f)).
3.2. Immunoregulatory KFD48490.1 Is an Active Chitinase of
T. suis L1 Larvae. Based on amino acid sequence similarity,
database research predicted KFD48490.1 was homologous
to acidic mammalian chitinase (AMCase) of T. trichiura
(Table 2). The amino acid sequence of KFD48490.1 revealed
the presence of the catalytic motive DxDxE (T. suis
DLDWE, Figure 2(a)), typically observed for active chiti-
nases, and a C-terminal chitin-binding domain with cysteine
residues responsible for the chitin binding (Figure 2(a)).
Alignment studies additionally proved high sequence simi-
larities to other known helminth chitinases including a puta-
tive endochitinase from the pig infecting Ascaris suum and a
glycosyl hydrolase from the human hookworm N. ameri-
canus (Figure 2(b)). Active chitinases cleave chitin from
the end of a polymer chain (exochitinase) and/or hydrolyse
small oligomers to generate N-acetylglucosamine monomers
within the oligomer chain (endochitinase) [49]. To examine
whether KFD48490.1 exerts true chitinase activity, we used
two different substrates, 4-MU-(GlcNAc)3 and 4-MU-
(GlcNAc)2, allowing us to evaluate both endo- and exochiti-
nase activity, respectively (Figure 2(c)). KFD48490.1 clearly
presented both, endo- and exochitinase activity, whereas
extensive, heat-induced proteolysis resulted in a loss of chit-
inase activity (Figure 2(c)).
With regard to the biology of nematodes, we explored
the influence of low pH and high temperatures hypothesiz-
ing that T. suis chitinase will be active at low pH and ele-
vated temperatures in the pig’s intestine to support larval
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hatching and development [50, 51]. Interestingly, KFD48490.1
remained enzymatically active over a wide range of pH4–7
(Figure 2(d)) and up to temperatures of 50°C (Figure 2(e)).
Together, these data confirmed the functional annotation
of KFD48490.1 as T. suis L1 true chitinase, and thus, the
protein is referred to as Ts-Chit from hereon.
3.3. T. suis Chitinase Does Not Act on DC Activation Marker
or T Cell Proliferation. Direct immunomodulatory effects of
ES or soluble proteins from adult and larval parasitic
nematodes have previously been shown in vitro, and various
modulatory activities were found such as targeting proin-

















































































OVA + alum i.p. OVA i.n. read out




















































































































Figure 1: T. suis L1 ES proteins are highly stage-specific, and candidates reduce allergic airway hyperreactivity when recombinantly
expressed and applied. (a) Protein ID counts resulting from proteomic MS-based analysis (see Supplementary Table S1) were compared
across the proteomic datasets of T. suis L1, L2, L3, and L4 ES proteins. Shown are protein IDs selected for recombinant expression. (b)
Expression cassette of LEXSY eukaryotic expression system illustrating positioning of the export signal peptide that mediates secretion
(SP), the selection antibiotic (nourseothricin, NTC), and the His6-tag for purification (H6). The cassette was integrated into the L.
tarentolae genome. (c) Silver-stained SDS/PAGE gel of recombinantly expressed T. suis L1 proteins. (d) Experimental setup of acute
ovalbumin- (OVA-) induced allergic airway hyperreactivity model and treatment regimen with recombinant T. suis proteins. Animals
were OVA-sensitized on days 0 and 14 and challenged with OVA intranasally on days 28 and 29. BAL fluid was collected from
pretreated or untreated animals at day 31. (e) Total number of cellular infiltrates in BAL fluid. Shown are nonallergic mice (PBS
controls), untreated allergic mice (OVA), and treatments with recombinant T. suis proteins indicated by GenBank IDs. (f) Numbers of
eosinophils in BAL fluid detected by differential cell counts of cytospin preparations stained with Diff-Quick over the different treatment
groups. Data shown are mean + SEM of n = 5–10 animals from 2 separate experiments. Statistically significant differences were
determined using a Kruskal-Wallis test (Dunn’s multiple comparisons test) and are indicated, ∗p ≤ 0:05.
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dendritic cells or macrophages and induction of arginase-1,
IL-10, and NO in macrophages [4, 31, 36, 52, 53], the
suppression of antigen-specific or unspecific CD4+ T cell
proliferation [54], or induction of Foxp3+ regulatory T cells
[19, 55]. Hence, we investigated T. suis chitinase (Ts-Chit)
activity on dendritic cell activation and T cell proliferation.
Recombinant Ts-Chit did not interfere with upregulation
of LPS- or CpG-induced activation markers on bone
marrow-derived dendritic cells (BMDC) such as MHCII,
CD86, or Ox40L (Figures 3(a) and 3(b)). While CpG-
induced proinflammatory cytokine expression was not
affected (Figure 3(c)), we observed reduced secretion of
LPS-induced IL-12p40 and TNFαwhen BMDC were treated
with Ts-Chit. We could also not detect induction of regu-
latory IL-10 in BMDC (Figure 3(c)). Similarly, TCR-
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Figure 2: KFD48490.1 is an active chitinase. (a) KFD48490.1 amino acid sequence with mapped signal peptide (red), catalytically active
residues (highlighted in blue and red), and the chitin-binding domain (black, italic). (b) Amino acid sequence alignment of KFD48490.1
and known nematode chitinases. (c) Fluorimetric chitinase assay testing recombinant KFD48490.1, heat-inactivated KFD48490.1, and a
chitinase control enzyme (ctrl) with substrates for endochitinase (left) and exochitinase (right) activity. Data shown are mean ± SD of n
= 3 replicates from one of three independent experiments. (d) Chitinase assay testing KFD48490.1 activity depending on pH (range 2-
10). (e) Chitinase assay testing KFD48490.1 preincubated at different temperatures (4–90°C) for 1 h prior to the assay. Data shown are
mean ± SD of n = 3 replicates.













































































































































































































































































































































































10 Journal of Immunology Research
not affected (Figures 3(d) and 3(e)) when cultured in the
presence of Ts-Chit. OVA-tg CD4+ T cells loaded onto
OVA-presenting BMDC resulted in similar proliferation
of OVA-recognizing T cells in both Ts-Chit-treated and
Ts-Chit-untreated cultures (Figures 3(f) and 3(g)). Again,
we did not observe significant effects on T cell polarization
(Figure 3(g)). Although a strong, direct immunomodula-
tory activity of Ts-Chit was not established by the
in vitro assays that we performed, we aimed to decipher
what caused the in vivo effects of the nematode chitinase
and went back to the mouse model of AHR.
3.4. T. suis Chitinase- (Ts-Chit-) Mediated Regulation of
Airway Hyperreactivity Only Partially Depends on Protein
Integrity. To investigate the effects of Ts-Chit treatment on
allergic airway disease, we analyzed airway resistance,
expiration time, and BAL fluid profiles in more detail.
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Figure 3: No direct effects of T. suis chitinase on DC activation or T cell proliferation. (a) Experimental setup of analyzing effects of Ts-Chit
on activation marker und cytokine release from bone marrow-derived dendritic cells. (b) MFI of MHCII, CD86, and Ox40L expression
analyzed by flow cytometry. Data are presented as individual values and mean ± SEM of n = 9 animals from n = 3 separate experiments.
(c) Cytokine levels of IL-6, IL-12p40, IL-10, and TNFα of BMDC supernatants harvested 24.5 h following TLR ligation and Ts-Chit
treatment detected by ELISA. Data are presented as individual values and mean ± SEM of n = 7-9 animals from n = 3 separate
experiments. Statistical significance was assessed using a two-tailed Mann-Whitney test, and results are indicated by ∗∗p ≤ 0:01. (d)
Experimental setup of analyzing effects of Ts-Chit on CD3e/CD28-induced T cell proliferation using CFSE-labeled splenocytes. (e)
Exemplary histogram of CFSE dilution in CD4+ T cells with (gray) and without (black) anti-CD3e/CD28 stimulation and summarized in
bar graphs for CD4 and CD8 T cell proliferation. Data are presented as individual values and mean ± SEM of n = 6 animals from n = 2
separate experiments. (f) Experimental setup of analyzing effects of Ts-Chit on antigen-dependent T cell proliferation and differentiation.
MACS-purified CD4+ T cells from DO11.10 mice were cocultured with OVA-loaded BMDC in the absence or presence of Ts-Chit. (g)
CFSE dilution of CD4+ T cells and transcription factor expression of Foxp3, Tbet, and GATA3 were analyzed in CFSElow CD4+ T cell
and were analyzed by flow cytometry and presented as summarized for n=5 mice from two independent experiments.
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heat-inactivated, recombinant Ts-Chit to assess whether
immunomodulatory effects were linked to the enzymatically
active T. suis chitinase protein.
Treatment of animals with intact and active Ts-Chit sig-
nificantly reduced the number of total cells (Figure 4(a)) and
eosinophils (Figure 4(b)) present in BAL fluid 2 days after
2nd OVA challenge. Differential cell counts of BAL fluid
further revealed that neutrophil numbers were largely
unaffected (Figure 4(c)). A trend towards an increase of
alveolar macrophage cell numbers was observed in Ts-Chit
compared to allergic (OVA) mice (Figure 4(d)). Flow
cytometry of BAL cells confirmed the reduced frequency
of eosinophils (CD45+CD11b+GR1lowCD11c-SiglecF+) in
Ts-Chit-treated compared to untreated (OVA) allergic
animals (Figures 4(e) and 4(f)) and also supported
increased frequencies of alveolar macrophages, identified as
CD11blowCD11c+ cells among CD45+ cells (Figure 4(g)), as
observed as a trend in differential cell counts. The respiratory
responses resulting from Ts-Chit treatment were measured
using noninvasive whole-body plethysmography 24 h after
OVA challenge. Importantly, also, the nonsensitized control
group (PBS) was intranasally challenged with OVA. Preven-
tative administration of Ts-Chit caused restoration of expira-
tion time to the level of PBS control mice at baseline
(Figure 4(h)). A trend in recovery was also noticed for treat-
ing with heat-inactivated Ts-Chit (Figure 4(h)). Measuring
airway resistance to increasing doses of methacholine
(MCh) revealed that Ts-Chit treatment attenuated exacer-
bation of MCh-induced airway hyperreactivity, but treat-
ment with inactivated Ts-Chit also had some effects
(Figures 4(h)–4(j)). We next evaluated whether the
reduced cellularity and improved lung function observed
in Ts-Chit-treated animals were reflected in BAL cytokine
levels. OVA sensitization and challenge caused a signifi-
cant increase of the cytokines IL-4, IL-5, and IL-13
detected in BAL fluid; however, Ts-Chit treatment did
not reduce but rather enhanced local Th2 cytokine pro-
duction (Figure 4(k)). Of note, TNFα levels in BAL did
not vary among groups (data not shown). Interestingly,
Ts-Chit and heat-inactivated Ts-Chit alike accelerated IL-
18 levels in BAL fluid (Figure 4(k)), a cytokine known to
induce IL-4, IL-5, and IL-13 release by mast cells and
basophils [56]. Thus, cellular infiltration and the respira-
tory response were improved in mice treated with Ts-Chit,
but Th2 cytokine level in BAL was unchanged or elevated
in comparison to untreated allergic mice (OVA). Pheno-
typing of lung inflammatory CD4 T cells revealed elevated
frequencies of IL-13-producing and GATA3-expressing
Th2 cells in mice receiving Ts-Chit or inactivated Ts-Chit
(Figure 4(l)), supporting our findings on enhanced local
Th2 responses in chitinase-treated mice independent from
the functional integrity of the nematode chitinase.
To further delineate the direct effects of Ts-Chit treat-
ment on lung inflammation of OVA-sensitized and OVA-
challenged mice, we investigated lung tissue pathology and
recruitment of alternatively activated macrophages (AAM).
While histopathological findings remained overall similar
in the lungs of untreated (OVA) and Ts-Chit-treated allergic
animals (Figure 5(a)), immunohistochemistry revealed
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Figure 4: Ts-Chit treatment mediates attenuation of airway hyperreactivity. Bronchoalveolar lavage (BAL) was performed two days after
OVA challenge, and the BAL fluid was examined for (a) total number of infiltrating cells (Neubauer chamber), (b) BAL eosinophils, (c)
BAL neutrophils, and (d) monocytes/macrophages using cytospin preparations and Diff-Quik staining. (e) Representative plots of BAL-
infiltrating cells using flow cytometry and focusing on eosinophil frequencies (identified as CD45+CD11b+GR1lowCD11c-SiglecF+).
Summary of flow cytometric analysis of (f) BAL eosinophils and (g) alveolar macrophages (CD45+CD11blowCD11c+). (h) Basal
expiration time during PBS inhalation measured using whole-body double-chamber plethysmography 24 h after OVA challenge. (i)
Concentration response curve of methacholine sensitivity. Specific airway resistance (Sraw) was assessed in response to increasing doses
of methacholine. (j) Sraw values recorded when nebulizing 50mg/ml of methacholine. (k) BAL cytokines detected two days after
challenge using bead-based multiplexing. (l) Exemplary contour plots showing IL-13/GATA3 coexpression among lung-infiltrating CD4+
T cells of allergic mice. Bar graph summarizes GATA3 frequency among CD4+Foxp3- T cells of lung lymphocytes of treatment groups
(n = 4–5 mice per group). (a–k) Data are presented as mean ± SEM of n = 10–12 animals from n = 3 separate experiments. Statistical
significance was assessed using a two-tailed Mann-Whitney test, and results are indicated by ∗p ≤ 0:05, ∗∗p ≤ 0:01, and ∗∗∗p ≤ 0:001.
































































































































































15Journal of Immunology Research
marker for AAM that mediates lung vascularization and tis-
sue repair [57, 58] when mice were treated with Ts-Chit
compared to OVA (Figures 5(b) and 5(c)). A similar trend
was observed for inactivated Ts-Chit-treated animals. Since
this was in contrast to our previous observation on Ts-ES
L1-induced suppression of RELMα+ cells [34] and given that
the resistin-like molecule (RELM) α is expressed not only in
macrophages but also in epithelial cells and tissue-
infiltrating eosinophils, we used smaller groups of mice to
define RELMα expression to a interstitial macrophage
phenotype by flow cytometry. Lung tissue macrophages
were analyzed in homogenates of lavaged lungs and defined
as EpCAM-CD11c+CD64+MHCII+SiglecF- (Figure 5(d)).
While overall frequencies of tissue macrophages were not
affected by Ts-Chit treatment (Figure 5(e)), we again
detected an increase in RELMα+ macrophages but did not
reach statistical significance (Figure 5(f)). However, we
found no indication for direct effects of Ts-Chit on RELMα+
expression in macrophages when analyzing RELMα+ mRNA
levels in bone marrow-derived macrophages stimulated with
recombinant Ts-Chit in vitro (data not shown).
Contrary to the increase of RELMα+ cells in the lung,
RT-PCR of homogenized lung tissue of all groups of mice
revealed downregulation of arginase-1 and MCP-1 mRNA
when mice were treated with intact and also inactivated
Ts-Chit compared to PBS (Figure 5(g)). Supporting reduced
numbers of eosinophil infiltration upon Ts-Chit treatment,
we detected downregulation of CCL11/eotaxin mRNA, a
potent eosinophil chemoattractant that stimulates recruit-
ment of eosinophils from the blood to sites of allergic
inflammation (Figure 5(e)). Together, these data illustrate
that protein integrity of the Ts-Chit is only partially respon-
sible for the treatment effects leading to attenuated airway
hyperreactivity.
3.5. T. suis Chitinase Treatment Interferes with Murine
Chitinase in AHR. From our in vitro and AHR experiments,
we concluded that a direct immunomodulatory effect of T.
suis chitinase or its chitinase activity was very unlikely. How-
ever, considering the high sequence similarities to known
chitinases and CLPs, we asked whether Ts-Chit treatment
of allergic mice interfered with the effector functions of its
murine counterpart, the acidic mammalian chitinase
(AMCase). AMCase is secreted by macrophages and epithe-
lial cells of the lung and gut and in the lungs constitutively
expressed and secreted into the airway lumen. STAT6-
activating signals, such as IL-13, further induce AMCase
expression, and elevated AMCase mRNA and protein levels
are detected in BAL of OVA-induced asthmatic mice [59].
Experimentally, the administration of anti-AMCase sera
was shown to reduce BAL and tissue eosinophilia and BAL
chitinase activity [59]. We therefore examined BAL fluid of
allergic mice for chitinase activity. And indeed, chitinase
activity was found to be reduced in the BAL of allergic mice
treated with intact and inactivated Ts-Chit compared to
untreated (OVA) mice (Figure 6(a)). In line with that, we
detected decreased AMCase transcript level (Chia1) mRNA
transcripts in lung tissue snips of allergic Ts-Chit-treated
compared to untreated (OVA) mice (Figure 6(b)). We there-
fore examined the implications of Ts-Chit treatment on the
family of murine chitinases and chitinase-like proteins

















































































Figure 5: Ts-Chit-mediated effects on lung parenchymal macrophages. (a) Histopathological evaluation of tissue inflammation. (b)
Histological sections of paraffin-embedded lung tissues from treated (Ts-Chit and Ts-Chit inact.), untreated (OVA), and nonsensitized
(PBS) controls stained for RELMα (red) and hematoxylin (steel blue) and presented at 400× magnification. (c) Histological
quantification of interstitial RELMα+ cells. (d) Gating strategy and representative plots of RELMα+ macrophages
(EpCAM-CD11c+CD64+MHCII+Siglec-) of lung homogenates from OVA-sensitized and challenged mice with or without Ts-Chit
treatment summarized in (e) and (f). (g) mRNA expression of arginase-1, monocyte chemotactic protein 1 (MCP1/CCL-2), and CCL-11/
eotaxin in lung tissue samples of mice from challenge experiments after lung lavage. Expression was normalized by using the
housekeeper gene peptidyl prolyl isomerase A (PPIA) and is presented as fold difference to the PBS control group. (a, c, g) Data are
presented as mean + SEM of n = 10–12 animals from n = 3 separate experiments. (d–f) Data are generated from n = 8–10 mice from two
independent experiments. Statistical significance was assessed using a two-tailed Mann-Whitney test and is indicated by ∗p ≤ 0:05 and
∗∗p ≤ 0:01.
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mediated allergic airway inflammation [60]. Interestingly, T.
suis chitinase was shown to have a high percentage of amino
acid sequence identity when compared to the two true
murine chitinases (AMCase (41.6%) and Chit1 (41.5%)) or
the murine CLPs Ym1 (39%), Ym2 (37.5%), or BRP-39
(36.7%) (Suppl. Fig. 2); its protein structure, however, is
not known so far.
3.6. T. suis Chitinase Reveals High Structural Similarity to
Murine Chitinase but Presents Dimeric Structure. To better
understand structural differences between nematode and
mammalian chitinases, we determined the crystal structure
of the nematode chitinase protein by X-ray crystallography.
The final model analysis data collection and refinement sta-
tistics are summarized in Table 3. They indicate that the
structure is of high resolution, that it is well refined to very
good statistics, and hence that it is of high quality. The over-
all structure reveals a TIM-barrel or (βα)8-barrel motif,
which means that 8 β-strands form the central barrel which
is surrounded by 8 α-helices (Figures 7(a) and 7(c)). The
active site with the sequence motif D149xD151xE153 is
depicted in Figure 7 A.2. The crystal structure furthermore
revealed a C2-symmetric dimer of the protein, which is
stabilized by an intermolecular disulfide bond formed by a
cysteine residue at position 180 (Figures 7 A.1 and 7(b)).
Such dimerization has not been described so far for human
or murine chitinases, nor has the occurrence of a cysteine
residue at position 180. In addition, the structural alignment
with human AMCase (3FXY), human chitotriosidase
(1GUV), human YKL-40 (1NWR), and murine Ym1
(1VF8) (Figure 7(c)) indicates highly similar structural fea-
tures in the core regions (marked in red) and certain areas,
mostly at the protein surface, where the structure differs
between nematode and mammalian chitinases (highlighted
in green/blue). A detailed structure-based sequence align-
ment of T. suis chitinase, mouse chitinases, and CLPs is
given in Supplementary S2. Notably, the C-terminal region
of Ts-Chit from amino acids 401 to 495 contains many thre-
onine repeats and is referred to as unordered region. The T.
suis chitinase dimerization was further examined by com-
paring reducing (+ β-mercaptoethanol) and nonreducing
(- β-mercaptoethanol) conditions for SDS/PAGE loading.
We indeed detected a second, higher band at around
75 kDa indicative for dimerization under nonreducing con-
ditions (Figure 7(d)).
Following the idea that T. suis interferes with murine
chitinase activity during allergic airway hyperreactivity, we
more specifically compared surface features of Ts-Chit and
AMCase (PDB: 3FY1), the only acidic chitinase with known
experimental 3D structure. To that effect, the surface electro-
statics for mammalian AMCase and the Ts-Chit monomer
were visualized and appraised. While investigating the
monomer alone did not reveal any strikingly identical sur-
face patches, looking at the dimerization region around α3/
α4-α3′/α4′ (α3:~127-142; α4:~161-180) revealed similarities
with an acidic surface patch of AMCase (Figure 8(a)).
In summary, this first crystallographic structure analysis
of a parasitic nematode chitinase revealed Ts-Chit dimeriza-
tion and the concomitant existence of surface patches absent
in the monomeric protein. The surface electrostatics of these
dimer-specific patches show a remarkable similarity between
T. suis chitinase and murine AMCase. The structural und
functional similarity of T. suis chitinase and murine AMCase
could either mean that Ts-Chit is sensed similar to murine
AMCase resulting in cumulative effects or in turn that Ts-
Chit interferes with murine AMCase function during lung
inflammation.
4. Discussion
An efficient strategy of parasitic nematodes to ensure sur-
vival, growth, and reproduction in immunocompetent
hosts involves immunoregulation of the host immune

















































































Figure 6: Ts-Chit treatment interferes with murine chitinase activity. (a) Chitinase assay testing BAL samples of allergic mice with
endochitinase substrate. Data shown are mean + SEM of n = 4–5 replicates. (b) mRNA expression of murine chitinase AMCase (Chia1)
in lung tissue samples of mice from AHR challenge experiments after lung lavage. Expression was normalized by using the housekeeper
gene peptidyl prolyl isomerase A (PPIA) and is presented as fold difference to the PBS group. Data are presented as mean + SEM of
n = 12 animals from n = 3 separate experiments. Data were analyzed statistically using an unpaired t-test.
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systems [61], parasitic nematodes release several products
(ES products) that shape their host immune response
[1]. It is those yet unidentified ES immunomodulatory
molecules that bear the therapeutic potential for targeting
immune-mediated diseases.
Following the complex life cycles of parasitic nematodes,
there is evidence for life cycle stage-specific expression and
release of distinct sets of ES molecules needed to fulfill spe-
cific tasks [31, 62, 63]. We have previously reported that
total ES proteins of the very early larval stage (L1) of the
whipworm T. suis very efficiently ameliorate allergic lung
disease in a model of OVA-induced AHR when applied dur-
ing the sensitization phase [34]. Notably, in TSO therapy for
indications such as ulcerative colitis, Crohn’s disease, or var-
ious autoimmune diseases including diabetes and multiple
sclerosis (MS), patients are repeatedly exposed to the early
larval stages of T. suis owing to the fact that T. suis only tran-
siently infects human intestines [23, 64]. Patients receiving
TSO therapy, however, seem to not equally benefit from
the worm therapy [22, 26–28]. In this context, we observed
a considerable degree of interindividual variability in the
adaptive immune responses to this helminth treatment
[29] suggesting that even how the anti-TSO response is
formed depends on the environmental and inflammatory
context of the individual treatment.
This led us to suggest a role for mediators being released
very early during infection by the first larval stages, and we
therefore focused on the identification of specific L1 ES
immunomodulators of T. suis and their potential immuno-
modulatory mechanisms. We compared ES proteins col-
lected from hatched L1 versus later larval stages (10, 18,
and 28 day old) isolated from the intestines of infected pigs
by using LC-MS/MS. Among the 33 proteins that were iden-
tified in the ES of in vitro-hatched T. suis L1, 8 proteins were
also found in the ES of L2 larvae, but no overlap to later lar-


























Figure 7: Three-dimensional structure ofT. suis chitinase (Ts-Chit). (a) Overall structure ofTs-Chit forming a C2-symmetric dimer (α-helices
in red, ß-strands in blue). The inset A.1 depicts the dimer-stabilizing disulfide bond-forming cysteine residue at position 180, while the inset
A.2 highlights the catalytic DxDxE center. (b) Ts-Chit dimer rotated by 90° compared to (a). (c) Ts-Chit monomer and its structural
alignment with AMCase (PDB Id 3FXY, [84]), human Chit1 (PDB-Id 1GUV, [85]), human YKL-40 (PDB-Id 1NWR, [86]), and murine
Ym1 (PDB-Id 1VF8, [87]). (d) Silver-stained SDS/PAGE gel of recombinantly expressed Ts-Chit (1 μg) under reducing (+ß-Merc.) and
nonreducing (-ß-Merc.) loading conditions.
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by the first two larval stages (L1 and L2), equipped with a
signal peptide and devoid of a transmembrane domain. A
large proportion of proteins detected in T. suis ES are not
encoded with a signal peptide, which is in line with reports
from other species [65–67]. Over the course of this study,
the genome of the porcine whipworm T. suis published in
2014 [68] had been complemented with two slightly larger
assemblies of male and female worms that in turn added
on to the number of identified protein IDs.
Screening six recombinantly expressed L1 ES proteins,
eukaryotically produced in L. tarentolae, in a model of
OVA-induced allergic airway hyperreactivity revealed that
the application of T. suis KFD48490.1 markedly reduced
inflammatory lung infiltrates, partly mimicking the effects
of total T. suis L1 ES [34]. Our results further proved that
KFD48490.1 is an enzymatically active chitinase of T. suis.
The enzyme retained its high activity in the pH range from
4 to 6 and thus is relatively resistant to acidic pH similar
to what has been documented for acidic mammalian chiti-
nases [69, 70].
Chitinases are glycosyl hydrolases (GH) with the ability
to directly degrade chitin polymers to low molecular weight
chitooligomers (reviewed in [71]). Based on amino acid
sequence similarity, the T. suis chitinase belongs to GH
family 18 characterized by an enzyme core of 8 β-strands
forming a barrel that is surrounded by α-helices, as well
as the conserved sequence DxDxE forming the active site.
Chitinases have essential roles in the life cycle of many par-
asites, supported by the existence of multiple genes as well
as tissue- and stage-specific expression patterns [72–74].
Chitinase activity in helminth biology is thought to be
essential during embryonic development, larval molting,
and degradation of the chitinous matrix [75, 76], suggesting
that chitinases might be attractive intervention targets [50].
In the context of allergic lung disease, however, chiti-
nases play a key role in mediating the Th2-driven inflamma-
tory responses commonly associated with asthma and have
been investigated to indicate disease severity [59, 77, 78].
Mice express two enzymatically active chitinases, acidic
mammalian chitinase (AMCase) and chitotriosidase (Chit),
and a set of enzymatically inactive chitinase-like proteins
(Ym1, Ym2, and BRP39). AMCase is secreted by macro-
phages and epithelial cells of the lung and gut. In the lungs,
it is constitutively expressed and secreted into the airway
lumen. STAT6-activating signals, such as IL-13, further
induce AMCase expression, and elevated AMCase mRNA
and protein levels are detected in BAL of OVA-induced
asthmatic mice [59]. Even though the mechanism of action
of most mammalian chitinases and CLPs is not fully under-
stood, stimulation of alveolar macrophages and enhancing
tissue inflammation are likely to be involved. Hartl and
coworkers [79] who showed that AMCase physically inter-
acts with epidermal growth factor receptor (EGFR) to
induce the production of, e.g., MCP-1, CCL17, and IL-8,
in lung epithelial cells also reported an autocrine and/or
paracrine feedback mechanism for AMCase in protecting
airway epithelial cells from Fas ligand- (FasL-) and growth
factor withdrawal-induced apoptosis [79, 80]. Therefore, it
is not surprising that blocking AMCase activity by admin-
istration of anti-AMCase sera reduced BAL and tissue
eosinophilia [59]. Similarly, in a gut inflammation model,
it has been shown that the panchitinase inhibitor caffeine







Trichuris suis chitinase dimer
(a)
(b)
Figure 8: Electrostatic surface representation of mammalian AMCase (PDB 3FY1) and the Ts-Chit dimer. (a) In the Ts-Chit dimer, a
surface patch of similar charge and shape as observed in mammalian AMCase is formed. The similar, acidic surface patch in both
molecules is circled. (b) Cartoon rendering of AMCase and Ts-Chit in the same orientation as in the upper panel. The location of the
circled residues in AMCase is highlighted in blue. Helices α3 and α4 contributing to the dimer formation in Ts-Chit are colored
turquoise and orange, respectively. The surface electrostatics were calculated with APBS and visualized with UCSF Chimera.
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We now demonstrate that treating mice with a worm-
derived chitinase from T. suis (Ts-Chit) during sensitization
reduced BAL infiltrates and eosinophilia, increased numbers
of RELMα+ interstitial cells, and improved overall lung func-
tion. Finding increased RELMα+ lung macrophages might
reflect an increased capacity of Ts-Chit-treated animals
to limit Th2-mediated inflammation and initiate tissue
repair [57].
Disease amelioration was linked to enhanced local Th2
responses in lung tissues, and heat-inactivated Ts-Chit was
able to partly phenocopy these effects in vivo, suggesting that
the functional chitinase domain is not entirely responsible
for the effects observed. Using different in vitro assays, we
investigated potential immunomodulatory effects of Ts-Chit
on DC and T cell activation but found no evidence for a
direct effect on immune cells as shown in other studies
[31, 55]. Yet, we cannot rule out any direct cellular effects
of Ts-Chit on mammalian cells.
Our in vivo results, however, suggest a mechanism
related to the one suggested by Zhu and colleagues [59]
that report on blocking AMCase activity using antiserum
treatment to reduce AHR severity. Similar to that study,
we show here that Ts-Chit treatment had no suppressive
effects on Th2 inductive responses such IL-4 and IL-13
as well as IL-5 levels. Zhu and coworkers further demon-
strated that anti-AMCase sera diminished the ability of
IL-13 to stimulate eotaxin and monocyte-chemotactic pro-
tein 1 (MCP-1), reflected by our results following treat-
ment with the worm chitinase. Besides anti-AMCase
treatment, other approaches have been used to address
AMCase activity, such as inhibition with small molecule
[82] or RNA interference [83], and demonstrated sup-
pressed eotaxin, MCP-1, and MIP-1ß levels when AMCase
activity or expression was inhibited.
Sequence alignment demonstrates a relatively high
degree of similarity between T. suis chitinase and AMCase,
but also to CLPs such as YM1, Ym2, or BRP39. Given the
high homology of T. suis and murine chitinases, both
summative and interfering effects would be conceivable.
Our in vivo observations on reduced chemokine expres-
sion and eosinophil infiltration, but nonsuppressed Th2
responses, rather points towards a scenario where treat-
ment with the worm chitinase interferes with the host’s
own chitinase activity triggered upon lung inflammation.
As a first indication, we observed decreased host chitinase
activity in BAL and a decrease in lung tissue AMCase
transcripts following treatment with the structurally highly
similar worm chitinase. Whether these findings are a con-
sequence of the overall reduced lung inflammation or
result from chitinase protein interference still needs to be
verified.
The X-ray crystal structure of Ts-Chit reported here con-
firmed the expected high structural similarity of the nema-
tode chitinase with murine acidic mammalian chitinase. In
addition, analysis of surface electrostatics of the Ts-Chit
dimer suggests the existence of an acidic surface patch on
the nematode protein that bears similarity to a surface fea-
ture on AMCase monomers. This might point to molecular
mimicry mechanisms, a phenomenon that is triggered by a
high degree of similarity of pathogen and host epitopes.
Future studies need to investigate whether structural similar-
ity between T. suis chitinase and murine chitinases or CLPs
is potentially linked to a serological response limiting activ-
ity of host AMCase similar to the study of Zhu and col-
leagues that applied anti-AMCase sera to ameliorate lung
inflammation [59].
5. Conclusion
In summary, we investigated L1 stage-specific, secreted pro-
teins of T. suis and their capacity for immunomodulation of
allergic lung disease.We identified an active chitinase ofT. suis
that, when applied during sensitization of an allergic response,
reduced eosinophilia and lung chemokine responses. These
findings add to our understanding of specific functions of
early secreted T. suis products in helminth biology and when
considered as therapeutics to create an anti-inflammatory
environment. The structural similarity between the worm
chitinase and its host equivalent, the absence of direct cellular
effects, and the potential to interfere with murine chitinase
activity suggest an alternative mechanism of Ts-Chit amelio-
rating OVA-induced, allergic lung disease that likely involves
structural mimicry. Such a mechanism of immunomodulation
could be one of those unrecognized strategies of mediating
anti-inflammatory responses.
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